- Home
- Publications
- Publication Search
- Publication Details
Title
The Quad Pill, a Once-Daily Combination Therapy for HIV Infection
Authors
Keywords
-
Journal
CLINICAL INFECTIOUS DISEASES
Volume 58, Issue 1, Pages 93-98
Publisher
Oxford University Press (OUP)
Online
2013-09-25
DOI
10.1093/cid/cit637
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Cobicistat on Glomerular Filtration Rate in Subjects With Normal and Impaired Renal Function
- (2012) Polina German et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks
- (2012) Paul E Sax et al. LANCET
- Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial
- (2012) Edwin DeJesus et al. LANCET
- Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection
- (2011) Calvin Cohen et al. AIDS
- Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143
- (2011) Mathieu Métifiot et al. AIDS
- Long-term Treatment With Raltegravir or Efavirenz Combined With Tenofovir/Emtricitabine for Treatment-Naive Human Immunodeficiency Virus-1–Infected Patients: 156-Week Results From STARTMRK
- (2011) Jürgen K. Rockstroh et al. CLINICAL INFECTIOUS DISEASES
- Clinical Pharmacokinetic and Pharmacodynamic Profile of the HIV Integrase Inhibitor Elvitegravir
- (2011) Srinivasan Ramanathan et al. CLINICAL PHARMACOKINETICS
- Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial
- (2011) Calvin J Cohen et al. LANCET
- Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study
- (2011) Jean-Michel Molina et al. LANCET INFECTIOUS DISEASES
- Secondary Integrase Resistance Mutations Found in HIV-1 Minority Quasispecies in Integrase Therapy-Naive Patients Have Little or No Effect on Susceptibility to Integrase Inhibitors
- (2010) F. Ceccherini-Silberstein et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Evolution of Integrase Resistance During Failure of Integrase Inhibitor-Based Antiretroviral Therapy
- (2010) Hiroyu Hatano et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Pharmacokinetics and Bioavailability of an Integrase and Novel Pharmacoenhancer-Containing Single-Tablet Fixed-Dose Combination Regimen for the Treatment of HIV
- (2010) Polina German et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Activity of Elvitegravir, a Once‐Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose‐Ranging Clinical Trial
- (2010) Andrew R. Zolopa et al. JOURNAL OF INFECTIOUS DISEASES
- Raltegravir: The First HIV Type 1 Integrase Inhibitor
- (2009) Charles Hicks et al. CLINICAL INFECTIOUS DISEASES
- Switch from Enfuvirtide to Raltegravir in Virologically Suppressed Multidrug‐Resistant HIV‐1–Infected Patients: A Randomized Open‐Label Trial
- (2009) Nathalie De Castro et al. CLINICAL INFECTIOUS DISEASES
- Pharmacokinetics and Pharmacodynamics of GS-9350: A Novel Pharmacokinetic Enhancer Without Anti-HIV Activity
- (2009) A A Mathias et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Greater Tenofovir‐Associated Renal Function Decline with Protease Inhibitor–Based versus Nonnucleoside Reverse‐Transcriptase Inhibitor–Based Therapy
- (2007) Miguel Goicoechea et al. JOURNAL OF INFECTIOUS DISEASES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started